A Study of Isoquercetin in People With Ovarian Cancer

This study is testing whether adding isoquercetin — a naturally occurring plant compound with anti-clotting and possibly anti-cancer properties — to standard chemotherapy can improve outcomes for women with ovarian cancer receiving first-line (initial) treatment. Researchers are also looking at whether it reduces dangerous blood clots, which are a common complication of both cancer and chemotherapy. **You may be eligible if...** - You have confirmed ovarian cancer (epithelial, serous, or clear cell type) - You are currently starting your first round of chemotherapy (isoquercetin would begin during cycle 1 or 2) - You are 18 or older with a life expectancy of more than 6 months - You are in good enough health (ECOG performance status below 2) - Your blood counts and organ function meet the minimum requirements **You may NOT be eligible if...** - You have already completed or are on a later line of chemotherapy - You have a different type of ovarian cancer (e.g., germ cell tumor) - You have serious bleeding disorders or are on certain blood thinners - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.